Faculty

Needs Statement

According to the American Society of Addiction Medicine, addiction is a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.  No single treatment is appropriate for everyone but treatment needs to be readily available and attend to multiple needs of the individual, not just his or her drug abuse and medications are an important element of treatment for many patients, especially when combined with counseling and other behavioral therapies. According to the National Survey on Drug Use and Health (NSDUH), 19.7 million American adults (aged 12 and older) battled a substance use disorder in 2017.  Almost 74% of adults suffering from a substance use disorder in 2017 struggled with an alcohol use disorder and about 38% of adults in 2017 battled an illicit drug use disorder.  That same year an estimated 20.7 million people age 12 and older needed treatment for a substance use disorder. Only 4 million people received treatment, or about 19% of those who needed it.  (www.drugabuse.gov). This activity should help participants:

• Define Addiction 
• Identify ways to manage addiction as a chronic disease
• Discuss the effect of drugs on the brain including dopamine and other neurotransmitters
• Demonstrate the process for initiating treatment for Opiate Use Disorder (OUD) with buprenorphine and extended release naltrexone
• Name 3 medications FDA approved to treat Alcohol Use Disorder
• Discuss other substances and current treatment recommendations
• Develop individualized plans of care for substance use treatment including medications and behavioral interventions
• Review process for treating opiate use disorder with Naltrexone vs Buprenorphine
• Identify how to obtain a waiver to prescribe buprenorphine and additional training resources

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, you will be able to:

• Define Addiction
• Identify ways to manage addiction as a chronic disease
• Discuss the effect of drugs on the brain including dopamine and other neurotransmitters
• Demonstrate the process for initiating treatment for Opiate Use Disorder (OUD) with buprenorphine and extended release naltrexone
• Name 3 medications FDA approved to treat Alcohol Use Disorder
• Discuss other substances and current treatment recommendations
• Develop individualized plans of care for substance use treatment including medications and behavioral interventions
• Review the process for treating opiate use disorder with Naltrexone vs Buprenorphine
• Identify how to obtain a waiver to prescribe buprenorphine and additional training resources

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0521-H1.0-UK13C

ACGME Competencies

• Patient care
• Medical knowledge
• Practice-based learning and improvement
• Interpersonal and communication skills
• Professionalism
• Systems-based practice

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication
• Teams and Teamwork

CPE
This knowledge-based activity will award 1.75 contact hours (0.175 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 1.75 ANCC contact hours.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 2.1 KBN contact hours.

Provider #: 3-0008-12-21-0056 . In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.

Other
UK Healthcare CECentral certifies this activity for 1.75 hours of participation.

KBSW
This activity has been approved by the Kentucky Board of Social Work for 1.75 hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

The activity is supported by Anthem.